InvestorsHub Logo
Followers 8
Posts 478
Boards Moderated 0
Alias Born 03/12/2016

Re: tredenwater2 post# 168561

Wednesday, 10/17/2018 12:02:09 PM

Wednesday, October 17, 2018 12:02:09 PM

Post# of 456878
Yes Tred, he is the presenter of a poster presentation.

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane
, MBBS FRANZCP1
, Michael Kornhauser BPharm1
, Ella Modini BSc1
, Harald Hampel, MD PhD2
, Stephan Toutain MS3
,
Christopher Missling PhD3
1
HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3
Anavex Life Sciences Corp., New York, USA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News